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Abstract 
Parkinson's disease (PD) is characterized by progressive loss of dopaminergic (DA) neurons in the 
substantia nigra. However, studies of post-mortem PD brains have shown that not only DA neurons 
but also the noradrenergic (NA) neurons in the locus coeruleus degenerate, and that the NA 
neurodegeneration may be as profound, and also precede degeneration of the midbrain DA 
neurons. Previous studies in animal models of PD have suggested that loss of forebrain NA will add 
to the development of motor symptoms in animals with lesions of the nigrostriatal DA neurons, but 
the results obtained in rodents have been inconclusive due to the shortcomings of the toxin, DSP-4, 
used to lesion the NA projections. Here, we have developed an alternative double-lesion paradigm 
using injections of 6-OHDA into striatum in combination with intraventricular injections of a 
powerful NA immunotoxin, anti-DBH-Saporin, to eliminate the NA neurons in the locus coeruleus, 
and associated pontine nuclei. Animals with combined DA and NA lesions were more prone to 
develop L-DOPA-induced dyskinesia, even at low L-DOPA doses, and they performed signiﬁcantly 
worse in tests of reﬂexive and skilled paw use, the stepping and staircase tests, compared to DA-only 
lesioned rats. Post-mortem analysis revealed that NA depletion did not affect the degree of DA 
depletion, or the loss of tyrosine hydroxylase-positive innervation in the striatum. Cell loss in the 
substantia nigra was similar in both single and double lesioned animals, showing that the worsening 
effect was not due to increased loss of nigral DA neurons. The results show that damage to 
brainstem NA neurons, contributes to the development of motor impairments and the appearance 
of L-DOPA-induced dyskinesia in 6-OHDA lesioned rats, and provide support for the view that the 
development of motor symptoms and dyskinetic side effects in PD patients reﬂects the combined 
loss of midbrain DA neurons and NA neurons. 
Introduction 
Parkinson's disease (PD) is a neurodegenerative disease associated with a profound loss of the 
dopaminergic (DA) neurons in the substantia nigra (SN). Current therapeutic strategies are mostly 
focused on pharmacological restoration of DA neurotransmission. However, studies of post-mortem 
PD brains have shown that not only DA neurons in the SN but also noradrenaline (NA) neurons in the 
locus coeruleus (LC) degenerate, and that NA neurodegeneration may be as profound, and also 
precede, degeneration of midbrain DA neurons (German et al., 1992; Patt and Gerhard, 1993; Zarow 
et al., 2003). The early involvement of the NA system is also in line with the caudal-to-rostral disease 
progression predicted by the model proposed by Braak et al.(Braak et al., 2003; Hawkes et al., 2007, 
2009). 
Studies in non-human primates have shown that NA neurodegeneration may contribute to the 
extent and severity of symptoms seen in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
model of PD. Mavridis and colleagues compared MPTP treated squirrel monkeys with monkeys 
treated with a combination of MPTP and 6-hydroxydopamine (6-OHDA) injected into the LC 
(Mavridis et al., 1991). Monkeys treated with MPTP alone showed motor deﬁcits that recovered 
over time, while the double lesioned monkeys developed more severe and persistent parkinsonian 
symptoms. In line with these observations, Piﬂ and col-leagues (Piﬂ et al., 2013) recently reported 
that in MPTP treated monkeys with near-complete (N95%) loss of striatal DA the severity and 
persistence of motor deﬁcits was correlated, not with the magnitude of DA depletion, but with the 
loss of NA in the motor thalamus, similar to the reductions seen in advanced PD patients (Piﬂ et al., 
2012). These observations suggest that severe long-lasting motor impairments in MPTP treated 
monkeys will develop only when the NA neurons are affected, in addition to the DA neuron cell loss. 
Studies on the effects of NA neuron loss on the development of motor impairments in rodent 
models of PD have used systemic injections of the toxin DSP-4 to lesion the NA neurons and their 
projections. In MPTP-treated mice Archer and Fredriksson (Archer and Fredriksson, 2006) have 
shown that the MPTP-induced motor deﬁcits are further aggravated in mice when MPTP was given 
in combination with the DSP-4. Similar effects have so far not been obtained using DSP-4 in rats. In a 
study using bilateral injections of 6-OHDA into the MFB, alone or in combination with DSP-4 
(Srinivasan and Schmidt, 2004) the effect of the combined lesion on motor behavior was limited to a 
reduction in open-ﬁeld locomotor activity. In two other studies the effect of DSP-4 on L-DOPA-
induced dyskinesia have been explored in rats injected with 6-OHDA into the MFB, but found no 
effect on dyskinesia (Miguelez et al., 2011; Perez et al., 2009). Thus, it remains unclear to what 
extent damage to the NA projections may contribute to the development of motor impairments and 
dyskinesia in rodent models of PD. 
A shortcoming of these rodent studies is the use of DSP-4 to lesion the NA projections. In mice, this 
toxin is relatively speciﬁcfor NA neurons at low to moderate doses, but when used in rats it has 
proved difﬁcult to obtain more substantial and long-lasting depletions of fore-brain NA without 
additional damage to the serotonin system (Archer and Fredriksson, 2006; Booze et al., 1988; 
Cassano et al., 2009; Dailly et al., 2006; Hughes and Stanford, 1998; Kask et al., 1997; Szot et al., 
2010; Thomas et al., 2007; Wolfman et al., 1994). Anti-dopamine-β-hydroxylase (DBH)-Saporin (here 
called DBH-Saporin) is an interesting alternative. This immunotoxin, which consists of a monoclonal 
antibody to DBH coupled by a disulﬁde bond to saporin (a ribosome inactivating protein), has been 
shown to be selectively toxic to NA neurons, and when injected into the ventricular space in rats it 
has been shown to be effective in killing the NA neurons in the LC, as well as the associated A5 and 
A7 pontine cell groups, eliminating the cell bodies without any detectable effect on other 
monoaminergic neurons in the brain (Coradazzi et al., 2010; Wrenn et al., 1996). The high selectivity 
and efﬁciency of the DBH-Saporin lesion makes it an ideal tool for studies involving lesions of the 
pontine NA neuron cell groups, but it has so far not been used to explore the role of NA neurons in 
the development of motor impairments and dyskinesia in the rat PD model. In this study we have 
used DBH-Saporin to obtain a near-complete lesion of the LC NA neurons bilaterally in 6-OHDA-
lesioned rats, and monitored the development of L-DOPA-induced dyskinesia in rats subjected to a 
single unilateral 6-OHDA lesion with that obtained in rats with combined 6-OHDA and DBH-Saporin 
lesions. In a second experiment we have compared the motor impairments induced by DA and 
combined DA + NA lesions in rats treated with 6-OHDA alone or with a combination of 6-OHDA and 
DBH-Saporin. The results show that damage to the NA neurons promotes the development of L-
DOPA-induced dyskinesia in rats with severe 6-OHDA lesions, and in addition has a worsening effect 
on motor impairments in rats with partial lesions of the nigrostriatal DA system. 
Material and methods 
Animals 
Adult female Sprague–Dawley rats (225–250 g at the start of the experiment, Charles River, Sweden) 
were used in the present study and housed on a 12 h light/dark cycle (light on 7:00–19:00) with free 
access to food and water. All animal works were performed in accordance with regulations set by 
Swedish legislation 1988:543 and EU-directive 2010/ 63. 
Drugs 
All the drugs were diluted in 0.9% sterile saline and injected s.c. un-less otherwise stated. 
Apomorphine (0.1 mg/kg in 0.002% L-ascorbic acid); benserazide (10 mg/kg); desipramine (20 
mg/kg, i.p.); and 6-OHDA (3.5 μg/μl free base in 0.02% L-ascorbic acid in 0.9% saline, into the 
striatum) were purchased from Sigma-Aldrich, Sweden. L-DOPA (6, 12, and 24 mg/kg); amphetamine 
(2.5 mg/kg, i.p.) and DBH-Saporin (2 × 2.5 μg in phosphate buffered saline (PBS) into 
lateralventricles, bilaterally) were purchased from Research Organics, Cleve-land, OH; 
Apoteksbolaget, Sweden; and Advanced Targeting Systems, San Diego, CA, USA, respectively. DSP-4 
(50, 75, and 100 mg/kg, i.p. was tested and 50 mg/kg was chosen due to mortality.) and reboxetine 
(3 and 10 mg/kg, 20 min before L-DOPA injection, i.p.) were purchased from Tocris Bioscience, 
Bristol, UK. 
Experimental design 
Before the two main experiments, the efﬁcacy of two NA toxins was compared. DSP-4 (50 mg/kg in 
saline, i.p.) and DBH-Saporin (2 × 2.5 μg per rat, bilaterally into the lateral ventricles) were injected 
into intact rats (n = 5 each). Four weeks after the injection, rats were sacriﬁced and sections 
throughout the brain (1 in 6 series) were stained with DBH antibody (Millipore AB, Sweden). To 
conﬁrm the NA depletion in DBH-Saporin rats, separate rats (n = 5) were injected with DBH-Saporin 
and 4 weeks later cortex and striatum were dissected for high performance liquid chromatography 
(HPLC) measurement of NA levels. 
Experiment 1 
Three groups of rats were included in this project (Fig. 1A). One group of rats (n = 8) received NA 
toxin DBH-Saporin into the ventricles bilaterally (for details, see below). After two weeks, two groups 
of rats (n = 8 each) received 6-OHDA into striatum (for details, see Lesion surgery). Three weeks after 
the 6-OHDA surgery, the degree of motor deficits was evaluated using four motor tests (stepping, 
cylinder, corridor, and amphetamine-induced rotation, each test was performed on different days). 
Then, rats were challenged with different doses of L-DOPA, apomorphine, and the NA transporter 
blocker, reboxetine. Three days after the last LID test, cortex and striatum were dissected for high 
per-ormance liquid chromatography (HPLC) to measure the level of NA, DA, and DOPAC. 
Experiment 2 
Two groups of rats (n = 18 in total) received DBH-Saporin into the ventricles bilaterally (Fig. 1B). 
After two weeks, two groups of rats (n = 30 in total) received 6-OHDA into striatum (for details, see 
Lesion surgery). Six weeks after the 6-OHDA injection, the degree of motor deﬁcits was evaluated 
using four motor tests (amphetamine-induced rotation, cylinder, corridor, and stepping test; each 
test was performed on different days). The rats that had received 6-OHDA only (n = 28) were divided 
into two groups evenly based on the four motor test results. One of the two groups (n = 13) was 
injected with DBH-Saporin into the lateral ventricles, as above. DBH-Saporin was injected before (n = 
12) or after (n = 13) 6-OHDA injection to investigate whether the effect of the toxin was dependent 
on the state of DA innervation at the time of injection. Four weeks after the injection, the rats went 
through a battery of motor tests. At the end of the motor tests, they were perfused and sections 
throughout the brain (1 in 6 series for each antibody) were stained with tyrosine hydroxylase (TH) 
and vesicular monoamine transporter (VMAT) antibodies for histological analysis. 
Lesion surgery 
Stereotaxic surgery was performed under general anesthesia, induced by i.p. injection (1.4–1.6 ml) 
of a 20:1 mixture of Fentanyl and Dormitor® (Apoteksbolaget, Sweden). For DBH-Saporin, 5 μg(in 
14μl of PBS) was injected bilaterally into the lateral ventricles, 2.5 μgon each side (AP = −0.6 mm 
from bregma; ML = ±1.5 from bregma; DV = −4.5 from the skull surface; tooth bar = 0.0; injection 
speed 2 μl/min) using a stereotaxic frame (Stoelting, Wood Dale, IL). In Experiment 1, a total of 28 μg 
6-OHDA (3.5 μg/μl free base in 0.02%L-ascorbic acid in 0.9% sterile saline) were injected into the 
striatum (AP/ML = +1.3/−2.6; +0.4/−3.2; −0.4/−4.2; and −1.3/−4.5 mm from bregma;DV= −5.0 mm 
from the dura surface; Tooth bar = 0.0; injection speed 1 μl/min). In Experiment 2, a total of 14 μg 6-
OHDA (3.5 μg/μl free base in 0.02% L-ascorbic acid in 0.9% sterile saline) were injected into the 
striatum (AP = ±0.5 mm from bregma; ML =3.2/−4.2 mm from bregma; DV = 
−5.0mmfromthedurasurface; Tooth bar = 0.0; injection speed 1 μl/min). To give less damage to the 
brain, a glass capillary (outer diameter 60–80 μm) was ﬁtted onto the needle of a Hamilton syringe 
(Nikkhah et al., 1994). In order to protect NA ﬁbers, the NA transporter blocker, desipramine (20 
mg/kg, i.p.)was given 30 min before the 6-OHDA injection. After the 6-OHDA injection, the needle 
was kept in place for an additional 3 min before retracted slowly. Antisedan® (0.28 mg/kg, s.c., 
Apoteksbolaget, Sweden) was injected to reverse sedative effects of anesthetics and Temgesic® 
(0.04 mg/kg, s.c., Apoteksbolaget, Sweden) to relieve pain after the surgery. 
 
 
 
 
 
Amphetamine-induced rotation 
Rats were administered 2.5 mg/kg of amphetamine sulphate (Apoteksbolaget, Sweden, i.p.) and left 
and right full body turns were recorded over 90 min using automated rotometer bowls (AccuScan 
Instrument Inc., Columbus, OH), as described previously (Ungerstedt and Arbuthnott, 1970). The 
data are expressed as net full body turns per min where rotation towards the lesion side (i.e. right 
hand side) was given a positive value. 
Cylinder test 
Spontaneous forelimb use was measured in the cylinder test (Schallert and Tillerson, 1999), as 
reported previously Kirik et al.(2001). Individual rats were placed in a glass cylinder (diameter 20 cm) 
and a total of 20 weight-bearing forepaw touches to the glass were recorded. The data are 
presented as percentage of left (impaired) forepaw contacts out of the total contacts. Symmetric use 
of the two forepaws would thus give a score of 50% (10 out of 20). 
Corridor task 
Lateralized sensorimotor response was evaluated using the corridor task, as ﬁrst described by Dowd 
et al. (2005). The rats were food restricted (6–8 g per day, food administered only after the 
completion of the daily test) and placed in a 150 cm long and 7 cm wide corridor, with 10 white 
plastic beakers equally spaced along each wall, each beaker containing 5–7 sugar pellets. The rats 
were given 5 min to investigate the corridor and make decisions to investigate beakers on either side 
of their body. The ratio of contralateral (left) investigations to the total is used for comparison. Rats 
were habituated in the corridor for the ﬁrst two days and the test was carried out for the next three 
days. Results were displayed as the average of the two most similar days. 
Stepping test 
Forelimb akinesia was assessed by the stepping test as described by Olsson et al. (1995). Rats were 
trained for 2 days and tested for the next 3 days (3 trials per day). The hind legs and one forepaw 
were held so that the animal has its weight only on one paw. Rats were encouraged to make 
reﬂexive adjusting steps when moved sideways along a 1 m table. Both limbs were tested in the 
forward and backward direction and the number of left paw (contralateral) forward adjusting steps 
was compared between groups. For statistical analysis the values from the last two days of testing 
were averaged together. 
Staircase test 
The staircase test, as ﬁrst described by Montoya et al. (1991), is speciﬁcally designed to test skilled 
forelimb motor movements. First, rats were food restricted throughout the test days (same regimen 
as in the corridor test, above) to encourage participation in the experiment, and put into a plastic 
staircase box loaded with sugar pellets for 20 minutes once a day for 13 days. Each box has a 
platform for the rat to lie on and a removable bilateral staircase ﬁlled with sugar pellets that are in 
reaching distance for the rat (for detailed information on the design of the test box, see ref). This 
test used 10 pellets on each step, with four total steps of increasing difﬁculty on each side of rat. At 
the end of the test session the remaining pellets were counted to see how many were retrieved, as 
well as how many pellets were dropped. The total amount of taken, eaten and dropped on the 
affected side was recorded as a measure of skilled forelimb use. For statistical analysis, the 3 most 
similar values of the ﬁnal 4 days were averaged together. 
L-DOPA-induced dyskinesia 
Abnormal involuntary movements (AIMs) were assessed by injecting escalating doses of L-DOPA (6, 
12, and 24 mg/kg) together with the peripheral DOPA-decarboxylase inhibitor, benserazide (10 
mg/kg). AIMs were evaluated according to the rat dyskinesia scale described in detail previously (Lee 
et al., 2000; Winkler et al., 2002) by an experimenter who was unaware of the identity of the 
animals. Brieﬂy, the animals were placed individually in transparent plastic cages without bedding 
material and scored every 20 min following the injection of L-DOPA until no AIMs were observed. 
The severity of the dyskinetic movements were scored as follows: 0, absent; 1, occasional (i.e. 
present less than 50% of the observation time); 2, frequent (i.e. present more than 50% of the 
observation time); 3, continuous but interrupted by strong sensory stimuli; 4, continuous and not 
interrupted by strong sensory stimuli. Scores were given in three sub-types of AIMs according to 
their topographic distribution as forelimb, orolingual, and axial together with locomotor behaviors 
(contralateral circular movement). Forelimb dyskinesia was deﬁned as movement of contralateral 
forelimb/paw with jerky, choreic, or dystonic character. Orolingual dyskinesia is predominantly seen 
as hyperkinesia with jaw movement, facial grimace, and tongue protrusion towards contralateral 
side. The axial dyskinesia is often of a dystonic type with torsion of the head, neck, and trunk 
towards contralateral side. Enhanced manifestations of normal behaviors such as grooming, 
gnawing, rearing and snifﬁng were not included in the rating. Total AIMs score was calculated by 
combining forelimb, orolingual and axial dyskinesia scores. 
Apomorphine-induced dyskinesia 
In order to evaluate DA receptor super sensitivity in striatum, apomorphine (0.1 mg/kg in 0.002% 
ascorbic acid) was administered s.c. and AIMs were monitored every 10 min following the drug 
injection, until the signs of AIMs had subsided, using the same rating scale as for LID. 
HPLC measurement 
To test the effect of DBH-Saporin on tissue neurotransmitter levels, rats were decapitated 4 weeks 
after toxin injection and cortex and striata were rapidly dissected out bilaterally, frozen on dry ice 
and stored in 80 °C freezer until analysis. For Experiment 1,rats were sacriﬁced 3 days after the last 
dyskinesia test and cortex and striata were rapidly dissected out, frozen and stored, same as the 
above. At the time of the analysis, tissues were homogenized by sonication in 0.1 N HClO4 (1:20, 
weight/volume), centrifuged at 10,000 ×g, the supernatant ﬁltered on micro spin centrifuge tubes 
(0.22 μmnylonﬁlter) and analyzed by HPLC with electrochemical detection. The HPLC system was 
equipped with 3.0 × 150 mm C18 (3.5 μ) Symmetry columns (Waters, Milan, Italy), kept at 35 °C by 
Series 1100 thermostat (Agilent Technol-ogies, Waldbronn, Germany), and ESA Coulochem II 
detector (Chelmford, MA, USA). The mobile phase consisted of 80 mM Na2HPO4, 0.27 mM EDTA, 0.6 
mM sodium octyl sulfate, 8% methanol, 3% acetonitrile, pH 2.8 with H3PO4, delivered at 0.35 
ml/min by a 1260 Inﬁnity pump (Agilent Technologies, Waldbronn, Germany). The Coulochem 
analytical cell ﬁrst electrode was set at +200 mV, the second one at −300 mV. Only the second 
electrode signal was recorded and analyzed. In these conditions, the detection limit (signal to noise 
ratio 3:1) was 0.3 pg on column. Data are expressed as pg/mg tissue. 
Perfusion 
At the end of the experiment animals received i.p. injection of sodium pentobarbitone (60 mg/kg, 
Apoteksbolget, Sweden) and were transcardially perfused with 100 ml of 0.9% saline followed by 
250 ml of ice-cold 4% paraformaldehyde (PFA) in PBS. The brains were removed and post-ﬁxed for 2 
hr in the same ﬁxative before cryoprotection in 25% sucrose in PBS overnight. 
Immunohistochemistry 
Cryoprotected brains were cut coronally at 35 μm thickness in 6 series using a freezing slide-
microtome (Leica) and free-ﬂoating sections were quenched for 15 min with 3% H2O2 and 10% 
methanol in potassium-PBS (KPBS). Sections were incubated with blocking solution (5% normal 
goat/horse serum and 0.25% tritonX-100 in KPBS) for 1 hr followed by primary antibodies (mouse 
anti-DBH, MAB308, Millipore, 1:1000; mouse anti-NeuN, MAB377, Millipore, 1:100; rabbit anti-TH, 
AB152, Millipore, 1:1000; rabbit anti-VMAT, AB81855, AbCam, 1:1000) in blocking solution overnight 
at room temperature. Next day, incubation in blocking solution with secondary antibodies (horse 
anti-mouse, BA 2000 or goat-anti rabbit, BA 1000, Vector Laboratories, 1:200) for 1 h at room 
temperature was followed by streptavidin-biotin complex solution (ABC Elite, Vector Laboratories) 
for 1 h. The visualization of the primary and secondary antibodies was carried out by peroxidase 
(0.01% H2O2) driven precipitation of di-amino-benzidine. The sections were mounted onto subbed 
slides and air-dried overnight before being dehydrated and cover slipped using DePeX mountant 
(BDH Chemicals, UK). 
Estimation of striatal DA ﬁbers using optical densitometry 
For densitometry TH+ stained striatal tissue sections were captured using a high-resolution scanner 
(Scanscope CS, Aperio Technologies, Oxford, UK). Using Image J software (National Institutes of 
Health, USA), the average optical density over the entire area of the striatum for three striatal 
sections in each animal was quantiﬁed: Rostral (+1.0 mm from Bregma), Medial (−0.26 mm from 
Bregma) and Caudal (−0.92 mm from Bregma) in each animal. To compensate for differences in 
background coloring between the slides, the optical den-sity was subtracted from values obtained in 
the cortex of each sample. The data is expressed as a percentage of the ﬁber density on the lesioned 
side to the non-lesioned side. 
Estimation of the amount of DA neurons in SN 
The total number of VMAT+ (DA) neurons in SN was assessed by stereology. Perfused brains were 
cut in a 1:6 series, which gave approximately 9 successive SN sections to analyze for each animal. 
Brieﬂy, using the Stereo Investigator software, the SN of each tissue section was highlighted 
bilaterally based on anatomical morphology (using histological references) as the sampling area. 
Next, it was decided how many sampling sites to visit for each SN section. To have conﬁdence that 
the sample population was representative of the true population, 100–150 cells were counted in 
each SN to reach a variance level of 0.10 or less, except in some cases where animals had too severe 
lesions to reach this number. The results are expressed as a total number of cells in the lesioned 
(right) SN, expressed as percentage of the number on the non-lesioned (left) side. 
Statistical analysis 
All data are expressed as mean ± the standard error of the mean. Statistical signiﬁcance was set at p 
b 0.05. Unpaired t test has been used for the HPLC data analysis of the pilot study. One-way analysis 
of variance (ANOVA) with Newman Keuls multiple comparisons test was used for amphetamine-
induced rotation, cylinder test, corridor task, stepping test, staircase test, L-DOPA-induced 
dyskinesia for total AIMs, apomorphine induced dyskinesia, TH densitometry, and VMAT+ cell counts 
to ﬁnd statistical differences in three or more groups. Two-way ANOVA with Bonferroni's multiple 
comparisons test was used for HPLC data from experiment 1, L-DOPA-induced dyskinesia (each com-
ponents data), and reboxetine data. For dyskinesia data, non-parametric test (L-DOPA-induced 
dyskinesia for total AIMs and apomorphine-induced dyskinesia: Kruskal-Wallis test with Dunn's 
multiple comparisons test; L-DOPA-induced dyskinesia (each components data): Mann–Whitney test 
for 6-OHDA and double lesioned pair; reboxetine data: Friedman test for each group) was applied to 
con-ﬁrm the statistical signiﬁcance. All statistics in this study were performed using Prism 6 for Mac 
OS X, version 6.0a (GraphPad Software, Inc.). 
Results 
Efﬁcacy of the two NA toxins 
Prior to the main experiments, DSP-4 and DBH-Saporin were com-pared for their ability to destroy 
NA neurons in the LC. DSP-4 has been widely used in order to deplete central NA levels in rodents 
and non-human primates. However, when used in rats, Szot and colleagues have reported that the 
effect of DSP-4 is transient and also not fully speciﬁc for the projections from the LC (Szot et al., 
2010). In this study the authors observed reduced NA levels in prefrontal cortex, hippocampus, 
amygdala, septum/bed nucleus of the stria terminalis, and cerebellum between 3 days and 2 weeks 
after the injection, followed by progressive recovery at later time points. By contrast, DBH-Saporin, 
given intraventricularly, has been reported to be a powerful toxin, able to completely wipe out the 
LC NA system in rats (Wrenn et al., 1996). This toxin, how-ever, has never been used in the context 
of 6-OHDA lesioned, parkinsonian animals. Hence, we were set to compare the efﬁcacy of these two 
toxins in order to assess whether DBH-Saporin could, indeed, yield more severe and long-lasting LC 
NA neuron degeneration in parkinsonian rats. 
In this test DSP-4 was administered i.p. at a dose of 50 mg/kg, and DBH-Saporin (2 × 2.5 μg) was 
injected bilaterally in the lateral ventri-cles. These doses were selected based on previous reports 
(Fritschy and Grzanna, 1989; Wrenn et al., 1996). In a pilot experiment we found that higher doses 
of DSP-4 (75 and 100 mg/kg) affected the survival of the animals (not shown). Four weeks later 
animals were sacriﬁced and the tissue was stained with DBH antibody. DBH immuno-histochemistry 
showed a striking difference between the two toxins: DBH-Saporin treatment removed all NA cell 
bodies in LC (Figs. 2B,D), while the LC remained virtually intact in the DSP-4 treated animals (Figs. 
2A,C). The complete loss of LC neurons, bilaterally, in the DBH-Saporin treated rats was conﬁrmed in 
sections stained for the pan-neuronal marker NeuN (not shown). Consistent with these data, HPLC 
measurements of tissue NA levels, performed in a separate group of DBH-Saporin treated rats, 
revealed a near-complete loss of NA in both cortex and striatum (Figs. 2E,F). 
After conﬁrming that DBH-Saporin given intraventricularly is an efﬁcient tool to obtain a near-
complete lesion of the NA neurons in the LC, two experiments were designed. In Experiment 1 we 
focused on the effect of NA neuron degeneration on L-DOPA-induced dyskinesia. This study was 
performed in rats with a severe 6-OHDA lesion; a total of 28 μg was distributed over four sites in the 
striatum, sufﬁcient to induce more prominent motor impairments and allow induction of L-DOPA-
induced dyskinesia in most of the treated animals (see Winkler et al., 2002). In Experiment 2 we used 
a lower dose of toxin; a total of 14 μg was distributed over two sites, in order to induce more 
moderate behavioural impairments. This would allow us to detect worsening of motor impairments 
in a situation more similar to that seen in early Parkinson patients. 
Experiment 1 
Effect of NA neuron degeneration on 6-OHDA-induced loss of striatal DA 
In Experiment 1 DBH-Saporin was administered 2 weeks before the 6-OHDA lesion and the extent of 
damage to the DA and NA neuronal projections were assessed by HPLC measurements of tissue 
levels of DA, DOPAC and NA, performed at the end of the 10 week experimental study. As shown in 
Figs. 3A,B, the level of DA in cortex and striatum was decreased by about 70–80% in both 6-OHDA 
lesioned groups, similar in magnitude in both single and double lesioned animals. This pat-tern was 
same for the DOPAC level in cortex (Fig. 3C) and striatum (Fig. 3D). Unexpectedly, there we observed 
an increased level of DA and DOPAC in contralateral side of the cortex in double lesioned animals. In 
the double lesioned group NA was reduced bilaterally by more than 99% in cortex and by more than 
80% in striatum, (Figs. 3E, F). In the 6-OHDA treated rats we used desipramine, a NA transporter 
blocker, to protect the NA neurons against the toxin. Nevertheless, the NA level was reduced by 
about 20% in the ipsilateral cortex in the animals treated with 6-OHDA alone (Fig. 3E). A minor 
reduction was seen also in striatum, but this did not reach signiﬁcance (Fig. 3F). 
 
 
 
 Effect of NA neuron degeneration on 6-OHDA-induced motor impairments Three weeks after the 6-
OHDA injection (5 weeks after DBH-Saporin injection), rats were subjected to four different 
behavioural tests. As shown in Fig. 4, the 6-OHDA lesioned rats were impaired in all four tests, but 
there was no signiﬁcant difference between single and double lesioned rats in any of the tests. In the 
amphetamine-induced rotation test (Fig. 4A) both 6-OHDA lesioned groups displayed a strong 
ipsilater-al rotation, more than 11 turns/min, thus conﬁrming the severity of the lesion induced by 
the high dose of the toxin. In the cylinder test (Fig. 4B), the use of the affected (left) paw was 
reduced by about 60%compared to the intact rats, similar in both single and double lesioned rats. In 
the corridor task (Fig. 4C), intact rats explored the two sides to a similar degree, i.e. 50% left side 
investigation, whereas the single and double lesioned rats had signiﬁcantly reduced left side 
investigation (15–17% left side investigation). In the stepping test (Fig. 4D), the intact rats made 
around 12 steps whereas the single and double lesioned rats made 1–2 steps. 
Effect of NA neuronal degeneration on L-DOPA-induced dyskinesia 
After completion of the motor tests the rats were subjected to daily L-DOPA treatment and the 
development of dyskinesia was monitored over 3 weeks (see Fig. 1A). 6, 12, and 24 mg/kg of L-DOPA 
(together with 10 mg/kg benserazide) was administered for 7 days, 10 days, and 7 days, respectively 
(Fig. 5J the dose was escalated once the AIMs score reached a plateau). At the lowest dose, 6 mg/kg, 
L-DOPA evoked mild-moderate dyskinesia in the double lesioned group, while the rats given 6-OHDA 
alone showed no or only mild dyskinetic response (Figs. 5A,D). At higher doses, 12 and 24 mg/kg 
(plus benserazide), L-DOPA evoked more severe dyskinesia in the double lesioned rats but only a 
low-to-moderate response in the single lesioned animals (Figs. 5B,E and C,F). The level of dyskinesia 
seen in the double lesioned rats was signiﬁcantly higher than that seen in 6-OHDA only and intact 
rats at the two lower doses. As seen in Figs. 5A–C the higher AIMs score in the double-lesioned 
group was due to an overall increase in the magnitude of dyskinesia at each time point, while the 
duration of the response was not affected. 
To investigate whether individual AIMs components were more or less affected by NA degeneration, 
scores were divided into three components (axial, limb, and orolingual dyskinesia). At 6 mg/kg of L-
DOPA, the limb and orolingual components were most prominently increased in the double lesioned 
animals (Fig. 5G), whereas in 12 mg/kg of L-DOPA, axial and orolingual dyskinesia were signiﬁcantly 
increased (Fig. 5H). The changes seen at the highest dose, 24 mg/kg, did not reach signiﬁcance (Fig. 
5I). 
To investigate to what extent this difference was due to a difference in sensitivity of postsynaptic DA 
receptors we administered the DA agonist apomorphine at a dose, 0.1 mg/kg, known to be effective 
in inducing dyskinesia in L-DOPA-primed 6-OHDA lesioned rats (Carta et al., 2007; Munoz et al., 
2009). Unlike L-DOPA, the level of dyskinesia induced by apomorphine was similar in the single and 
double lesioned groups (Fig. 5K), suggesting similar sensitization of post-synaptic DA receptors, 
which is in agreement with HPLC data showing equal degree of striatal DA depletion in both groups. 
 
It has been suggested that NA terminals might be involved in the elimination of extracellular DA, 
formed from L-DOPA, via the NA trans-porter. Indeed, there is a microdialysis study in 6-OHDA 
lesioned rats showing increased extracellular DA levels in the striatum when rats were pretreated 
with a NA transporter blocker, prior to L-DOPA administration (Arai et al., 2008). If this is the case, 
the L-DOPA-derived extra-cellular levels would be increased in the double lesioned rats, which in 
turn could lead to more severe dyskinesia. To investigate this possibility, we pretreated the rats with 
a NA transporter blocker, reboxetine at two doses, 3 and 10 mg/kg, shown to be effective in 
previous studies (Masana et al., 2011; Ortega et al., 2010; Sacchetti et al., 1999), and the dyskinesia 
induced by L-DOPA at 12 mg/kg was monitored. Contrary to the hypothesis, reboxetine did not 
worsen dyskinesia in the 6-OHDA rats (Fig. 5L), suggesting that clearance of DA by uptake into NA 
terminals does not account for the difference in the level of dyskinesia seen in the single and double 
lesioned rats. 
Experiment 2 
Effect of NA deﬁciency on DA-dependent motor behavior 
In this experiment we used a less severe 6-OHDA lesion (2 × 7 μg unilaterally in the striatum) in order 
to induce more moderate behavioural deﬁcits than those obtained in Experiment 1. DBH-Saporin 
was injected either 2 weeks before or 9 weeks after 6-OHDA to study whether the effect of the toxin 
was dependent on the state of DA innervation at the time of injection (see Fig. 1B). The rats were 
perfused for immunohisto chemical analysis 26 weeks after the 6-OHDA lesion. The integrity of the 
DA system was investigated by assessment of TH+ ﬁber density in striatum and by stereological 
counting of VMAT+ cell numbers in SN (Figs. 6H–K). Figs. 6A-E illustrate the extent of TH+ ﬁber loss in 
the striatum from representative TH-immunostained sections and the loss of TH+ cell bodies in the 
SN from each group, while 
 
  
 
  
  
 Figs. 6F,G show the loss of TH+ cell bodies in the LC, bilaterally, in DBH-Saporin treated and intact 
rats. All DBH-Saporin treated rats had maxi-mum 1–2 NA cells in each stained section. 
The loss of VMAT+ cells in the SN was similar in all three groups, ranging from 40–95%, with an 
average of about 80% (Fig. 6K). The loss of TH+ innervation in the striatum was greatest in the caudal 
and medial parts, ranging from about 60–100%, and less pronounced in the rostral striatum, limited 
to less than 50% in most cases (Figs. 6H-J). The loss of striatal innervation was similar in all three DA-
lesioned groups. 
The effect of DBH-Saporin-induced loss of LC NA neurons on motor performance, on the side 
contralateral to the 6-OHDA lesion, was studied in 5 different behavioural tests. Four of the tests 
(Figs. 7A–D) –amphetamine rotation, cylinder test, corridor task and stepping test –were the same 
as in Experiment 1. In addition, we added a test of more complex motor performance, the staircase 
test, which involves skilled paw use for retrieval of pellets and is acquired through training (Figs. 7E–
H). The three DA-lesioned groups (6-OHDA-injected groups with or without DBH-Saporin) showed 
impaired performance in the amphetamine rotation, cylinder, and stepping test but not in the 
corridor task. The turning response seen in the amphetamine rotation test (Fig. 7A) was less (around 
6–7 turns/min) than in the more severely lesioned rats used in Experiment 1 (Fig. 4A, around 10–15 
turns/min). Compared to the pronounced effects seen in Experiment 1, the impairment was overall 
less severe in these rats, which had received a lower dose of 6-OHDA. No signiﬁcant difference was 
found in the motor performance between single lesioned (6-OHDA) and double lesioned (Saporin + 
6-OHDA and 6-OHDA + Saporin) groups in the amphetamine-induced rotation (Fig. 7A), cylinder (Fig. 
7B), and corridor (Fig. 7C) tests. By contrast, double lesioned rats (either Saporin+ 6-OHDA, or 6-
OHDA + Saporin, or both) showed more severe motor deﬁcits compared to the 6-OHDA only injected 
rats in the stepping (Fig. 7D) and staircase (Figs. 7E–H) tests. Overall, with the exception of the 
stepping test, DBH-Saporin injection appeared to induce equal deﬁcits whether it was injected 
before or after the 6-OHDA lesion. 
Daily performance in the staircase test (Figs. 7E,F) showed similar acquisition of the task between 
the 6-OHDA and the Intact group over the 13 days of training. The Saporin group performed worse in 
the be-ginning but reached a similar level at later days of testing. The two dou-ble lesioned groups 
learned slowly and never reached the same level of performance as the other groups. Hence, when 
we compared the number of pellets taken during the last 4 days, both the Saporin + 6-OHDA and the 
6-OHDA + Saporin group performed signiﬁcantly worse than other groups (Fig. 7G). Daily 
performance in the number of pellets eaten showed a similar trend as pellets taken (Fig. 7H), 
although the data from the last 4 days did not show statistical signiﬁcance between the Saporin + 6-
OHDA and the 6-OHDA group. 
The scatter plots in Fig. 8 show the individual scores of the rats in the staircase test (last four days) 
plotted against the loss of DA neurons in the SN (Figs. 8A,B) and against the loss of TH+ innervation 
in the striatum (Figs. 8C,D). The performance of the 6-OHDA only lesioned rats (red circles) was 
unaffected by the lesion. Their scores, above 30 pellets taken, and above 20 pellets eaten, were 
within the range seen in the In-tact control group (see dashed lines) regardless of the magnitude of 
cell loss or striatal denervation, which varied from about 60 to 90% in the individual cases. By 
contrast, most of the double-lesioned rats (blue triangles, both groups combined) showed a 
markedly impaired performance already at moderate levels of damage to the nigrotriatal neurons, 
i.e. at 75–90% loss of DA neurons in the SN and 50–80% loss of striatal TH+ innervation, suggesting 
that loss of NA neurons in the LC affects the ability of the 6-OHDA lesioned rats to acquire and 
perform this more complex motor task. 
 
Discussion 
In this study we demonstrate for the ﬁrst time that the selective NA toxin DBH-Saporin, contrary to 
DSP-4, is highly effective in removing NA neurons in 6-OHDA-lesioned rats, and that the profound NA 
neuron loss induced by this toxin has signiﬁcant impact on the development of L-DOPA-induced 
dyskinesia and motor impairments, as observed in tests of reﬂexive and skilled paw use. The 
worsening of L-DOPA-induced dyskinesia and motor impairments observed in parkinsonian rats after 
DBH-Saporin treatment does not appear to be due to de-creased survival of nigral DA neurons, 
neither when DBH-Saporin was given before 6-OHDA, nor when given after the DA toxin. 
Accordingly, neither the striatal DA ﬁbre density nor DA tissue content in cortex and striatum was 
changed. 
Previous studies of the effect of NA depletion on the development of L-DOPA-induced dyskinesia in 
6-OHDA lesioned animals have been contradictory. Both Fulceri et al. (2007) and Barnum et al. 
(2012) have used 6-OHDA injected into the MFB, with or without systemic injection of the uptake 
blocker desipramine (to protect NA terminals) in order to achieve DA depletion with or without loss 
of forebrain NA. The former study reported more severe dyskinesia in double lesioned group while 
the latter study saw the opposite result: decreased dyskinesia in double lesioned group. In a third 
study, Perez et al. (2009) reported that L-DOPA-induced dyskinesia remained unchanged after DSP-4 
injection in 6-OHDA lesioned rats. In a different study, when DSP-4 was administered into L-DOPA-
primed, 6-OHDA-lesioned dyskinetic rats, the degree of dyskinesia was unchanged; however, when 
LC NA neurons were re-moved by ibotenic acid in already dyskinetic rats, there was an increase of 
the overall AIMs score due to the prolongation of dyskinesia (Miguelez et al., 2011). 
These contradictory results are most probably due to the variable magnitude of NA depletion, and 
LC NA neuron damage in particular, obtained with the different types of lesion used. From the 
recent study of Szot et al. (2010) it seems likely that the long-term reduction of NA in the target 
regions of LC (cortex and hippocampus) induced by DSP-4 at the dose used in these studies (50 
mg/kg) was less than 50%. In the present study we used the DBH-Saporin immunotoxin to obtain a 
near complete destruction of the NA neurons, resulting in a ≥90% reduction of NA in both cortex and 
striatum. The worsening of L-DOPA-induced dyskinesia induced by severe damage to the NA 
projections from the LC neurons, as seen here, is consistent with the observations of Fulceri et al. 
(2007) in MFB-6-OHDA lesioned rats. In their study a loss of around 80% of striatal NA (as seen in the 
rats that did not receive the protective desipramine treatment) was associated with an in-creased 
level of dyskinesia. 
The mechanism underlying this effect is not clear. Our results show, for the ﬁrst time, that increased 
dyskinesia in NA + DA double lesioned rats is not due to increased sensitization of postsynaptic DA 
receptors, or to reduced elimination of L-DOPA-derived DA. Thus, the dyskinesia in-duced by a low 
dose of the DA receptor agonist apomorphine was similar in both single and double lesioned rats, 
and blockade of the NA transporter by reboxetine did not induce any worsening of L-DOPA-induced 
dyskinesia in single lesioned animals. This argues against the hypothesis that L-DOPA-derived DA, in 
part, is eliminated by uptake into NA terminals, and that removal of the NA innervation will result in 
an increased level of L-DOPA-derived DA acting on the supersensitive DA receptors. 
As DA appears to bind to NA receptors (Cornil and Ball, 2008), it could also be hypothesized that 
stimulation of supersensitive NA receptors by L-DOPA-derived DA may be involved in the increased 
LID in double lesioned rats. However, this seems unlikely under our experimental conditions, as 
apomorphine has been shown to have similar afﬁnity to NA receptors as DA itself (Cornil and Ball, 
2008), but no difference was found between the two lesioned groups after its administration, in con-
trary to L-DOPA. As discussed below, available data speak in favor of an alternative mechanism, i.e., 
that the effect on the development of dyskinesia induced by the loss of NA neurons is an indirect 
one, mediated by changes in the activity of either the DA neurons themselves, or of neurons 
involved in the regulation of basal ganglia function, such as the raphe serotonergic neurons, the SN 
pars reticulata neurons, or the corticostriatal neurons. 
In our second experiment, the effect of NA neuron degeneration on motor impairment was 
investigated. Double lesioned rats performed signiﬁcantly worse in reﬂexive and skilled paw use 
tasks. The effect was especially clear in staircase test. Regardless of the magnitude of DA 
degeneration in nigra and striatum, single lesioned rats did not show any impairment in retrieving 
and eating pellets, whereas most of the double lesioned rats showed impairments in both 
parameters. In previous studies in rats, using 6-OHDA lesions in combination with DSP-4, the 
behavioural deﬁcits induced by the 6-OHDA lesion was largely unaffected by the DSP-4 treatment 
(Delaville et al., 2012; Srinivasan and Schmidt, 2003, 2004), although one of them reported reduced 
open ﬁeld activity in 6-OHDA + DSP-4 double lesioned rats (Srinivasan and Schmidt, 2004). In mouse 
and monkey models the effects of NA degeneration, induced by DSP-4 or 6-OHDA into LC, have been 
more consistent and pronounced, especially when MPTP has been employed as a DA toxin. In both 
models (monkey and mouse), NA degeneration prevented spontaneous recovery of DA after MPTP 
and induced more pronounced motor deﬁcits (Archer and Fredriksson, 2006; Bing et al., 1994; Fornai 
et al., 1997; Mavridis et al., 1991). In our study, increased motor impairments did not seem to be 
caused by increased DA neuron cell loss, which is in agreement with some studies (Delaville et al., 
2012; Piﬂ et al., 2013; Rommelfanger et al., 2007). Other studies have reported increased DA 
neurodegeneration, or increased loss of striatal DA, in double lesioned animals (Archer and 
Fredriksson, 2006; Bing et al., 1994; Fornai et al., 1997; Mavridis et al., 1991; Srinivasan and Schmidt, 
2003, 2004). It remains unclear, however, to what extent this effect on DA neurodegeneration is 
mediated via damage to the NA projections, or due to a direct, non-speciﬁcinsult of the DSP-4 toxin 
on DA neurons made vulnerable by the damage induced by the 6-OHDA treatment. 
The worsening of 6-OHDA-induced motor impairments induced by the loss of NA neurons is most 
likely mediated by changes in the activity of either the DA neurons themselves, or of neurons 
involved in the regulation of basal ganglia function, such as the serotonergic raphe neurons, the 
neurons in SN pars reticulata, or the cortical projection neurons innervating the striatum. LC NA 
neurons are known to innervate the SN pars compacta (Berridge and Waterhouse, 2003; Jones and 
Moore, 1977). Accordingly, NA has been shown to facilitate DA transmission in rats (Antelman and 
Caggiula, 1977; Donaldson et al., 1976; Ponzio et al., 1981; Reisine et al., 1982), and lesions of NA 
neurons and their terminals have been shown to decrease striatal DA release in rats (Lategan et al., 
1990, 1992; Marien et al., 1994). In addition, NA seems to be involved also in modulating the activity 
of other types of neurons, such as SN pars reticulata neurons and cortical pyramidal neurons. For 
instance, bilateral lesions of LC NA neurons with 6-OHDA in DA lesioned rats increased the ﬁring 
activity of SN pars reticulata neurons (Wang et al., 2010a) and medial prefrontal cortex pyramidal 
neurons (Wang et al., 2010b). In addition, ﬁring rate of serotonin neurons (Haddjeri et al., 1996; 
Svensson et al., 1975; Vandermaelen and Aghajanian, 1983) and serotonin synthesis and release 
(Adell and Artigas, 1999; Amargos-Bosch et al., 2003; Mongeau et al., 1997; Pudovkina et al., 2002, 
2003; Yoshioka et al., 1992) has been shown to be modiﬁed by NA input. All of these types of 
neurons are known to be involved in the expression of both L-DOPA-induced dyskinesia and motor 
performance. Thus, the loss of NA neurons, as seen in the double lesioned rats as well as in PD 
patients, is likely to induce functional changes not only in the surviving nigral DA neurons, but also in 
other subsets of neurons involved in the regulation of basal ganglia function. 
In conclusion, the potent and selective effect of DBH-Saporin on NA neurons provides a new efﬁcient 
tool to study the motor and non-motor implications of NA neuron degeneration in both intact and 
parkinsonian a nimals. Our results add to the increasing body of evidence suggesting that NA neuron 
loss, which is known to affect the PD brain already at a relatively early stage of the disease, may 
contribute to the development of L-DOPA-induced dyskinesia and the motor manifestations of the 
disease. Our data do not support a direct effect of NA on DA cell survival but may suggest an effect 
mediated by functional changes in neuons involved in basal ganglia function, including the surviving 
nigral DA neurons themselves. 
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